Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Charles River Laboratories International stock

Own Charles River Laboratories International stock in just a few minutes.

Fact checked

Charles River Laboratories International, Inc is a diagnostics & research business based in the US. Charles River Laboratories International shares (CRL) are listed on the NYSE and all prices are listed in US Dollars. Charles River Laboratories International employs 17,100 staff and has a trailing 12-month revenue of around USD$2.9 billion.

How to buy shares in Charles River Laboratories International

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Charles River Laboratories International. Find the stock by name or ticker symbol: CRL. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Charles River Laboratories International reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Charles River Laboratories International, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Charles River Laboratories International. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Charles River Laboratories International share price

Use our graph to track the performance of CRL stocks over time.

Charles River Laboratories International shares at a glance

Information last updated 2021-02-24.
52-week rangeUSD$95.58 - USD$303.79
50-day moving average USD$274.2485
200-day moving average USD$241.1644
Wall St. target priceUSD$328
PE ratio 39.3028
Dividend yield N/A (0%)
Earnings per share (TTM) USD$7.2

Buy Charles River Laboratories International shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Charles River Laboratories International stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Charles River Laboratories International under- or over-valued?

Valuing Charles River Laboratories International stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Charles River Laboratories International's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Charles River Laboratories International's P/E ratio

Charles River Laboratories International's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 39x. In other words, Charles River Laboratories International shares trade at around 39x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Charles River Laboratories International's PEG ratio

Charles River Laboratories International's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.1793. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Charles River Laboratories International's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Charles River Laboratories International's EBITDA

Charles River Laboratories International's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$677.3 million.

The EBITDA is a measure of a Charles River Laboratories International's overall financial performance and is widely used to measure a its profitability.

Charles River Laboratories International financials

Revenue TTM USD$2.9 billion
Operating margin TTM 15.13%
Gross profit TTM USD$1.1 billion
Return on assets TTM 5.43%
Return on equity TTM 19.17%
Profit margin 12.46%
Book value $42.49
Market capitalisation USD$14.1 billion

TTM: trailing 12 months

Shorting Charles River Laboratories International shares

There are currently 554,809 Charles River Laboratories International shares held short by investors – that's known as Charles River Laboratories International's "short interest". This figure is 19.4% down from 688,572 last month.

There are a few different ways that this level of interest in shorting Charles River Laboratories International shares can be evaluated.

Charles River Laboratories International's "short interest ratio" (SIR)

Charles River Laboratories International's "short interest ratio" (SIR) is the quantity of Charles River Laboratories International shares currently shorted divided by the average quantity of Charles River Laboratories International shares traded daily (recently around 293549.73544974). Charles River Laboratories International's SIR currently stands at 1.89. In other words for every 100,000 Charles River Laboratories International shares traded daily on the market, roughly 1890 shares are currently held short.

However Charles River Laboratories International's short interest can also be evaluated against the total number of Charles River Laboratories International shares, or, against the total number of tradable Charles River Laboratories International shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Charles River Laboratories International's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Charles River Laboratories International shares in existence, roughly 10 shares are currently held short) or 0.0127% of the tradable shares (for every 100,000 tradable Charles River Laboratories International shares, roughly 13 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Charles River Laboratories International.

Find out more about how you can short Charles River Laboratories International stock.

Charles River Laboratories International share dividends

We're not expecting Charles River Laboratories International to pay a dividend over the next 12 months.

Charles River Laboratories International share price volatility

Over the last 12 months, Charles River Laboratories International's shares have ranged in value from as little as $95.58 up to $303.79. A popular way to gauge a stock's volatility is its "beta".

CRL.US volatility(beta: 1.09)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Charles River Laboratories International's is 1.0902. This would suggest that Charles River Laboratories International's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Charles River Laboratories International overview

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company has a strategic partnership with PathoQuest SAS to establish a sequencing based testing laboratory; and an agreement with Algernon Pharmaceuticals Inc. for preclinical studies of AP-188 (N,N-Dimethyltryptamine) for the company's stroke clinical research program. Charles River Laboratories International, Inc. is based in Wilmington, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site